The Drugs of Abuse (DoA) biochips permit the analysis of up to 10 drug classes from a single patient sample providing rapid and accurate testing.
Randox biochip array technology (randox.com) is based on tried and tested ELISA methods. Each 9x9mm biochip comprises up to 25 discrete test regions (DTRs) on which immobilised antibodies specific to each biomarker are contained. In addition, two DTRs are reserved for quality control testing. The Drugs of Abuse biochip arrays demonstrate superior assay performance and also show excellent correlation with GC/MS.
Two Drugs of Abuse biochip arrays are available; DoA array I contains, amphetamine, methamphetamine, barbituates, benzodiazepine 1 & 2, Cannabinoids, cocaine metabolite, methadone, opiates and phencyclidine. DoA array II enables testing for buprenorphine, fentanyl, generic opioids, ketamine, LSD, MDMA, methaqualone, oxycodone 1 & 2 and propoxyphene. As a further feature, creatinine is included on the arrays as a marker of adulteration when testing urine samples. Both biochip arrays are validated for use with urine and whole blood. The use of oral fluid as a sample matrix is validated on DoA array I and currently in development for DoA array II.
Three revolutionary biochip analysers have been developed and can be employed for the Drugs of Abuse arrays. The fully automated Evidence was designed for high throughput laboratories and requires as little as 7µl of urine for all 10 drug classes. This rapid testing platform generates 1088 tests per hour. Once samples are loaded onto the Evidence, the doors are locked and the PC interface is password protected providing chain of custody information. The semi-automated Evidence Investigator for medium size labs and the point of application Evidence MultiStat analyser which generates results in 20 minutes are also available.
The revolutionary Randox Drugs of Abuse biochip array technology will ensure accurate and rapid drug screening guaranteeing confidence in results and ultimately saving valuable time and reducing costs.